Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis

被引:28
作者
Chen, Nan [1 ]
Liu, Shuai [1 ]
Huang, Lin [1 ]
Li, Wanling [1 ]
Yang, Wenhao [1 ]
Cong, Tianxin [1 ]
Ding, Lin [1 ]
Qiu, Meng [1 ,2 ]
机构
[1] Sichuan Univ, West China Hosp, West China Sch Med, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Med Oncol,Canc Ctr, Chengdu, Sichuan, Peoples R China
关键词
inflammation; malignant pleural mesothelioma; neutrophil-to-lymphocyte ratio; prognosis; meta-analysis; PROGRESSION-FREE SURVIVAL; NEUTROPHIL/LYMPHOCYTE RATIO; INFLAMMATION; CANCER; PARAMETERS; MARKERS; INDEX;
D O I
10.18632/oncotarget.15404
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Systemic inflammation responses can be reflected by peripheral blood count and combine index like the neutrophil-to-lymphocyte (NLR). The NLR has been reported to be a poor prognostic indicator in cancer recently. However, the prognostic effect of the NLR in patients with malignant pleural mesothelioma (MPM) still unclear yet. We conducted this meta-analysis aiming to evaluate the pooled value of NLR in prognosis as well as clinical characteristics in malignant pleural mesothelioma. A total of 11 studies with 1533 patients were included in this meta-analysis, in which 10 studies investigated the prognosis role of NLR using hazard ratio (HR) and 95% confidence intervals (95% CI). The elevated NLR was detected to be associated with a poor overall survival (OS)(HR = 1.48, 95% CI = 1.16-1.89, P < 0.001). The significant prognostic roles of NLR were also indicated in subgroup analyses. NLR level was also associated with histology instead of gender, stage or performance status (PS) score. These findings suggested that the elevated NLR could be a potential prognostic factor for malignant pleural mesothelioma patients and might be associated with histology as an efficient clinical index to stratify patients.
引用
收藏
页码:57460 / 57469
页数:10
相关论文
共 37 条
  • [1] The value of inflammatory parameters in the prognosis of malignant mesothelioma
    Abakay, Ozlem
    Tanrikulu, Abdullah Cetin
    Palanci, Yilmaz
    Abakay, Abdurrahman
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2014, 42 (02) : 554 - 565
  • [2] [Anonymous], SCI REP UK
  • [3] Inflammation and cancer: back to Virchow?
    Balkwill, F
    Mantovani, A
    [J]. LANCET, 2001, 357 (9255) : 539 - 545
  • [4] Cancer-Related Inflammation
    Candido, Juliana
    Hagemann, Thorsten
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 : S79 - S84
  • [5] Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma
    Cedres, S.
    Montero, M. A.
    Zamora, E.
    Martinez, A.
    Martinez, P.
    Farinas, L.
    Navarro, A.
    Torrejon, D.
    Gabaldon, A.
    Ramon y Cajal, S.
    Felip, E.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2014, 16 (09) : 776 - 782
  • [6] Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)
    Cedres, S.
    Montero, M. A.
    Martinez, P.
    Martinez, A.
    Rodriguez-Freixinos, V.
    Torrejon, D.
    Gabaldon, A.
    Salcedo, M.
    Ramon y Cajal, S.
    Felip, E.
    [J]. LUNG CANCER, 2012, 77 (01) : 192 - 198
  • [7] Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis
    Cheng, Hao
    Long, Feiwu
    Jaiswar, Mukesh
    Yang, Lie
    Wang, Cun
    Zhou, Zongguang
    [J]. SCIENTIFIC REPORTS, 2015, 5
  • [8] Relationship Between Prognosis and Neutrophil: Lymphocyte and Platelet: Lymphocyte Ratios in Patients with Malignant Pleural Mesotheliomas
    Cihan, Yasemin Benderli
    Ozturk, Ahmet
    Mutlu, Hasan
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (05) : 2061 - 2067
  • [9] Inflammation and cancer
    Eiro, Noemi
    Vizoso, Francisco J.
    [J]. WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2012, 4 (03): : 62 - 72
  • [10] A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: A combined analysis of 10 EORTC trials
    Francart, J.
    Vaes, E.
    Henrard, S.
    Legrand, C.
    Baas, P.
    Gaafar, R.
    van Meerbeeck, J. P.
    Sylvester, R.
    Robert, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (13) : 2304 - 2311